Certara (NASDAQ:CERT) Stock Price Down 3.8% – Should You Sell?

Certara, Inc. (NASDAQ:CERT) was down 3.8% during mid-day trading on Tuesday . The company traded as low as $11.47 and last traded at $11.33. Approximately 25,688 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 1,306,831 shares. The stock had previously closed at $11.78.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Tuesday, May 6th. William Blair restated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Stephens reaffirmed an “overweight” rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. KeyCorp upped their price objective on Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. Finally, TD Cowen started coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price for the company. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Certara has an average rating of “Moderate Buy” and an average price target of $15.67.

Certara Stock Down 1.7%

The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -57.88, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a 50 day moving average price of $11.73 and a 200 day moving average price of $11.75.

Certara (NASDAQ:CERT) last posted its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same period last year, the company earned $0.10 EPS. The firm’s revenue was up 9.7% compared to the same quarter last year. As a group, analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CERT. Blue Trust Inc. grew its stake in Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after acquiring an additional 822 shares during the period. KBC Group NV lifted its holdings in shares of Certara by 64.1% in the 4th quarter. KBC Group NV now owns 7,998 shares of the company’s stock worth $85,000 after purchasing an additional 3,125 shares in the last quarter. Choreo LLC lifted its holdings in shares of Certara by 25.0% in the 4th quarter. Choreo LLC now owns 50,582 shares of the company’s stock worth $533,000 after purchasing an additional 10,118 shares in the last quarter. Moloney Securities Asset Management LLC acquired a new stake in Certara in the 4th quarter valued at $128,000. Finally, Summit Trail Advisors LLC bought a new stake in Certara during the 4th quarter valued at $138,000. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.